Go Pro

CAMP4 Therapeutics (CAMP) 10K Form and Latest SEC Filings 2026

CAMP4 Therapeutics logo
$3.80 +0.01 (+0.26%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$3.94 +0.14 (+3.76%)
As of 08:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest CAMP4 Therapeutics SEC Filings & Recent Activity

CAMP4 Therapeutics (NASDAQ:CAMP) has submitted 336+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in CAMP4 Therapeutics's financial statements. The most recent filing was a Form 15-12G submitted on August 1, 2024.

DateFilerForm TypeView
08/01/2024 5:06 AM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2024 5:07 AM
CAMP4 Therapeutics (730255) Filer
Form 15-12G
07/21/2024 11:15 PM
CAMP4 Therapeutics (730255) Filer
Form EFFECT
07/17/2024 4:25 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/28/2024 8:38 AM
CAMP4 Therapeutics (730255) Subject
Nasdaq Stock Market LLC (1354457) Filed by
Form 25-NSE
06/06/2024 8:00 AM
CAMP4 Therapeutics (730255) Issuer
Cohenour Jason (1600926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024 4:40 PM
CAMP4 Therapeutics (730255) Subject
Cohenour Jason (1600926) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2024 3:36 PM
CAMP4 Therapeutics (730255) Issuer
Frizzley Jill Kathleen (1798190) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/03/2024 3:38 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2024 8:20 AM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2024 5:07 PM
CAMP4 Therapeutics (730255) Issuer
Kim Jikun (1488531) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2024 3:30 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/07/2024 6:41 PM
CAMP4 Therapeutics (730255) Issuer
Cohenour Jason (1600926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2024 8:01 AM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/25/2024 4:29 PM
Adams Christopher R. (2009128) Reporting
CAMP4 Therapeutics (730255) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/19/2024 3:30 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/09/2024 3:30 PM
CAMP4 Therapeutics (730255) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
01/09/2024 3:30 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2024 5:30 AM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/21/2023 9:34 AM
CAMP4 Therapeutics (730255) Subject
HIRSCHMAN ORIN (1131362) Filed by
Form SC 13G/A
12/18/2023 3:30 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/12/2023 3:31 PM
CAMP4 Therapeutics (730255) Filer
Form DEF 14A
12/12/2023 3:32 PM
CAMP4 Therapeutics (730255) Filer
Form DEFA14A
12/01/2023 3:30 PM
CAMP4 Therapeutics (730255) Filer
Form PRE 14A
11/07/2023 1:48 PM
CAMP4 Therapeutics (730255) Issuer
Scott Richard M. (1927117) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/25/2023 5:56 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2023 3:39 PM
Aristotle Capital Boston, LLC (1633911) Filed by
CAMP4 Therapeutics (730255) Subject
Form SC 13G/A
10/10/2023 11:44 AM
CAMP4 Therapeutics (730255) Issuer
Cohenour Jason (1600926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/10/2023 10:53 AM
CAMP4 Therapeutics (730255) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/05/2023 3:27 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/14/2023 3:17 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2023 3:48 PM
CAMP4 Therapeutics (730255) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/08/2023 3:35 PM
CAMP4 Therapeutics (730255) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/08/2023 3:39 PM
CAMP4 Therapeutics (730255) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/07/2023 11:37 AM
CAMP4 Therapeutics (730255) Issuer
Carson Brennen (1934952) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

CAMP4 Therapeutics SEC Filings - Frequently Asked Questions

CAMP4 Therapeutics (CAMP) has submitted 336+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

CAMP4 Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on CAMP4 Therapeutics's financial statements page.

The most recent filing was a Form 15-12G submitted on August 1, 2024. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:CAMP are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 8/1/2024. New filings are added as they're published.
From Our Partners